Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis

Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective treatment strategies. Herein, we discuss a recent report of a series of patients who were managed using a novel approach that involved personalized abatacept dosing, ruxolitinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Douglas B., Menzies, Alexander M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088759/
https://www.ncbi.nlm.nih.gov/pubmed/37041273
http://dx.doi.org/10.1038/s41571-023-00762-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088759/
https://www.ncbi.nlm.nih.gov/pubmed/37041273
http://dx.doi.org/10.1038/s41571-023-00762-1

Ejemplares similares